Literature DB >> 22752992

Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe.

Wiebren A Tjalma1, Alison Fiander, Olaf Reich, Ned Powell, Andrzej M Nowakowski, Benny Kirschner, Robert Koiss, John O'Leary, Elmar A Joura, Mats Rosenlund, Brigitte Colau, Doris Schledermann, Kersti Kukk, Vasileia Damaskou, Maria Repanti, Radu Vladareanu, Larisa Kolomiets, Alevtina Savicheva, Elena Shipitsyna, Jaume Ordi, Anco Molijn, Wim Quint, Alice Raillard, Dominique Rosillon, Sabrina Collas De Souza, David Jenkins, Katsiaryna Holl.   

Abstract

Knowledge of differences in human papillomavirus (HPV)-type prevalence between high-grade cervical intraepithelial neoplasia (HG-CIN) and invasive cervical cancer (ICC) is crucial for understanding the natural history of HPV-infected cervical lesions and the potential impact of HPV vaccination on cervical cancer prevention. More than 6,000 women diagnosed with HG-CIN or ICC from 17 European countries were enrolled in two parallel cross-sectional studies (108288/108290). Centralised histopathology review and standardised HPV-DNA typing were applied to formalin-fixed paraffin-embedded cervical specimens dated 2001-2008. The pooled prevalence of individual HPV types was estimated using meta-analytic methods. A total of 3,103 women were diagnosed with HG-CIN and a total of 3,162 with ICC (median ages: 34 and 49 years, respectively), of which 98.5 and 91.8% were HPV-positive, respectively. The most common HPV types in women with HG-CIN were HPV16/33/31 (59.9/10.5/9.0%) and in ICC were HPV16/18/45 (63.3/15.2/5.3%). In squamous cell carcinomas, HPV16/18/33 were most frequent (66.2/10.8/5.3%), and in adenocarcinomas, HPV16/18/45 (54.2/40.4/8.3%). The prevalence of HPV16/18/45 was 1.1/3.5/2.5 times higher in ICC than in HG-CIN. The difference in age at diagnosis between CIN3 and squamous cervical cancer for HPV18 (9 years) was significantly less compared to HPV31/33/'other' (23/20/17 years), and for HPV45 (1 year) than HPV16/31/33/'other' (15/23/20/17 years). In Europe, HPV16 predominates in both HG-CIN and ICC, whereas HPV18/45 are associated with a low median age of ICC. HPV18/45 are more frequent in ICC than HG-CIN and associated with a high median age of HG-CIN, with a narrow age interval between HG-CIN and ICC detection. These findings support the need for primary prevention of HPV16/18/45-related cervical lesions.
Copyright © 2012 UICC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22752992     DOI: 10.1002/ijc.27713

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  66 in total

1.  Current views and perspectives on classification of squamous intraepithelial lesions of the head and neck.

Authors:  Nina Gale; Nina Zidar; Mario Poljak; Antonio Cardesa
Journal:  Head Neck Pathol       Date:  2014-03-05

2.  Prognostic value of human papillomavirus 16/18 genotyping in low-grade cervical lesions preceded by mildly abnormal cytology.

Authors:  Jing Ye; Bei Cheng; Yi-Fan Cheng; Ye-Li Yao; Xing Xie; Wei-Guo Lu; Xiao-Dong Cheng
Journal:  J Zhejiang Univ Sci B       Date:  2017 Mar.       Impact factor: 3.066

3.  The value of improving failures within a cervical cancer screening program: an example from Norway.

Authors:  Emily A Burger; Jane J Kim
Journal:  Int J Cancer       Date:  2014-03-20       Impact factor: 7.396

4.  Targeted immunotherapy of high-grade cervical intra-epithelial neoplasia: Expectations from clinical trials.

Authors:  Jean-Luc Brun; José Rajaonarison; Nicolas Nocart; Laura Hoarau; Stéphanie Brun; Isabelle Garrigue
Journal:  Mol Clin Oncol       Date:  2017-12-08

5.  Racial/ethnic variation in the prevalence of vaccine-related human papillomavirus genotypes.

Authors:  Jane R Montealegre; Indu Varier; Christina G Bracamontes; Laura M Dillon; Martial Guillaud; Andrew G Sikora; Michele Follen; Karen Adler-Storthz; Michael E Scheurer
Journal:  Ethn Health       Date:  2017-09-04       Impact factor: 2.772

6.  Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNA.

Authors:  Frank Struyf; Brigitte Colau; Cosette M Wheeler; Paulo Naud; Suzanne Garland; Wim Quint; Song-Nan Chow; Jorge Salmerón; Matti Lehtinen; M Rowena Del Rosario-Raymundo; Jorma Paavonen; Júlio C Teixeira; Maria Julieta Germar; Klaus Peters; S Rachel Skinner; Genara Limson; Xavier Castellsagué; Willy A J Poppe; Brian Ramjattan; Terry D Klein; Tino F Schwarz; Archana Chatterjee; Wiebren A A Tjalma; Francisco Diaz-Mitoma; David J M Lewis; Diane M Harper; Anco Molijn; Leen-Jan van Doorn; Marie-Pierre David; Gary Dubin
Journal:  Clin Vaccine Immunol       Date:  2014-12-24

7.  Human papillomavirus in high-grade cervical lesions: Austrian data of a European multicentre study.

Authors:  Lucia Rössler; Olaf Reich; Reinhard Horvat; Sabrina Collas de Souza; Katsyarina Holl; Elmar A Joura
Journal:  Wien Klin Wochenschr       Date:  2013-09-17       Impact factor: 1.704

8.  A human papilloma virus testing algorithm comprising a combination of the L1 broad-spectrum SPF10 PCR assay and a novel E6 high-risk multiplex type-specific genotyping PCR assay.

Authors:  Dirk van Alewijk; Bernhard Kleter; Maarten Vent; Jean-Marc Delroisse; Maurits de Koning; Leen-Jan van Doorn; Wim Quint; Brigitte Colau
Journal:  J Clin Microbiol       Date:  2013-01-30       Impact factor: 5.948

9.  Alinity m HR HPV Assay Fulfills Criteria for Human Papillomavirus Test Requirements in Cervical Cancer Screening Settings.

Authors:  Anja Oštrbenk Valenčak; Anja Šterbenc; Katja Seme; Mario Poljak
Journal:  J Clin Microbiol       Date:  2019-12-23       Impact factor: 5.948

10.  Risk of HPV-16/18 Infections and Associated Cervical Abnormalities in Women Seropositive for Naturally Acquired Antibodies: Pooled Analysis Based on Control Arms of Two Large Clinical Trials.

Authors:  Mahboobeh Safaeian; Xavier Castellsagué; Allan Hildesheim; Sholom Wacholder; Mark H Schiffman; Marie-Cécile Bozonnat; Laurence Baril; Dominique Rosillon
Journal:  J Infect Dis       Date:  2018-06-05       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.